Vir Biotechnology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Vir Biotechnology sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Vir Biotechnology: 13 sponsored US clinical trials, 3 recruiting.

Vir Biotechnology sponsors 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV I Infection, with 1 trials.

Top-decile sponsor footprint

Vir Biotechnology ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395
RECRUITING Phase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615
RECRUITING Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

NCT05484206
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

NCT06903338
ACTIVE NOT RECRUITING Phase 2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

NCT04856085
COMPLETED Phase 1

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

NCT05844228
TERMINATED Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
TERMINATED Phase 1

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
COMPLETED Phase 1

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

NCT04988152
TERMINATED Phase 3

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675
COMPLETED Phase 2

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

NCT04779879
COMPLETED Phase 1

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

NCT04725877
COMPLETED Phase 2

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 4
Phase 3 2

Therapeutic Areas

HIV I Infection 1
Viral Hepatitis 1
EGFR 1
EGFR Positive Solid Tumors 1
Hormone-refractory Prostate Cancer 1
Hepatitis B， Chronic 1
Hepatic Impairment 1
Solid Tumor Malignancies 1
Cirrhosis 1
COVID-19 1

What is open in the Vir Biotechnology pipeline

3 recruiting of 13 indexed (23% open); 5 completed (38%).

Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: HIV I Infection (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vir Biotechnology: open-pipeline peers nationwide

Peers matched on 13 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Vir Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1015202530 0%5%10%15%20%25% Total trials Recruiting share Vir BiotechnologyAdaptimmuneAgennixAkili Interactive LabsAlumisClemson UniversityLiberating TechnologiesRahul AggarwalSequenom
Vir Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vir Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Vir Biotechnology page

13 registered trials is a research-attention snapshot, not an endorsement of Vir Biotechnology or any single study.

  • 3 of Vir Biotechnology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV I Infection is the condition Vir Biotechnology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV I Infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vir Biotechnology pipeline card: 13 registered trials from official public datasets.Report a data error.